CSL Nabs First ‘Direct Access’ Funding Agreement In France For Its Gene Therapy

CSL’s hemophilia B gene therapy Hemgenix is the first medicine to be granted reimbursement through France’s experimental “direct access” program, several months after England’s HTA body dubbed the one-time product too expensive for national funding.

3d rendered medical illustration of a sickle cell
• Source: Shutterstock

Hemgenix (etranacogene dezaparvovec), a one-time gene therapy from CSL Behring that has a US list price of $3.5m, has been granted full reimbursement for up to a year in France through a an exceptional access scheme launched two years ago.

France’s direct access program was introduced under a social security financing law that was passed in December 2021 (LFSS 2022)....

More from Health Technology Assessment

More from Market Access

Kennedy Appears Ill-Informed On Major Pharma Priorities, Creating Unique Lobbying Dynamics

 

The Health and Human Services Secretary made incorrect statements about the status of key industry priorities at a recent House hearing, which actually may be a good thing for drug sponsors.

How Could MFN Pricing Impact Commercial Market?

 
• By 

Industry experts forecast the impact of President Trump's Most-Favored Nation drug pricing policy on the commercial insurance industry.

Medicare’s Combo Products Negotiation Plan Conflicts With US FDA Standards, Firms Argue

 
• By 

The plan could curtail a period of pricing flexibility for newer subcutaneous versions of important oncology drugs.